TY  - GEN
AU  - Hirbe,Angela C.
AU  - Pratilas,Christine A.
AU  - Dodd,Rebecca D.
AU  - Hirbe,Angela C.
AU  - Pratilas,Christine A.
AU  - Dodd,Rebecca D.
TI  - Genomics and Models of Nerve Sheath Tumors
SN  - books978-3-03943-490-9
PY  - 2020///
CY  - Basel, Switzerland
PB  - MDPI - Multidisciplinary Digital Publishing Institute
KW  - Medicine
KW  - bicssc
KW  - neurofibromatosis type 1
KW  - nerve sheath tumor
KW  - cancer
KW  - latent variables
KW  - machine learning
KW  - supervised learning
KW  - transfer learning
KW  - random forest
KW  - metaVIPER
KW  - tumor deconvolution
KW  - neurofibromatosis
KW  - malignant peripheral nerve sheath tumor
KW  - MPNST
KW  - polycomb repressive complex
KW  - PRC2
KW  - NF1
KW  - kinase
KW  - kinome adaptation
KW  - kinome reprogramming
KW  - MET
KW  - MEK
KW  - doxorubicin
KW  - capmatinib
KW  - tram
KW  - genomics
KW  - tumor evolution
KW  - pathology
KW  - next generation sequencing
KW  - clinical genetics
KW  - malignant peripheral nerve sheath tumors
KW  - plexiform neurofibromas
KW  - Schwann cells
KW  - neurofibromatosis type 1 syndrome
KW  - neurofibromin 1
KW  - genetically engineered mouse models
KW  - heterogeneity
KW  - CRISPR/Cas9
KW  - mouse models
KW  - sarcoma
KW  - tumor microenvironment
KW  - neurofibromatosis 1 (NF1)
KW  - mebendazole (MBZ)
KW  - COX-2 inhibitor
KW  - malignancy
KW  - chemoprevention
KW  - nerve sheath tumors
N1  - Open Access
N2  - Nerve sheath tumors can be a significant cause of morbidity for many patients. These include benign tumors such as schwannomas, diffuse and plexiform neurofibromas, and atypical neurofibromas, as well as the aggressive soft tissue sarcoma known as the malignant peripheral nerve sheath tumor (MPNST). Nerve sheath tumors occur sporadically and in the context of the clinical neuro-genetic tumor predisposition syndromes neurofibromatosis type 1 (NF1) and type 2 (NF2). Historically, the mainstay of treatment for nerve sheath tumors has been surgery. However, for both benign and malignant nerve sheath tumors, there is a high recurrence rate, highlighting the pressing need for novel therapies. As we have entered the genomic era, the hope is that an improved understanding of the genetics, and therefore the biology, of these tumors will ultimately lead to therapies that result in better outcomes. In this Special Issue, we include both review articles and original research related to the genomic understanding and modeling of schwannomas, plexiform and diffuse neurofibromas, atypical neurofibromas, and malignant peripheral nerve sheath tumors as well as genomic methods being developed and applied to advance our understanding of these tumors
UR  - https://mdpi.com/books/pdfview/book/3090
UR  - https://directory.doabooks.org/handle/20.500.12854/69300
ER  -